Q-omics provides the consensus-scored PHYKPL profile across patient tissues and cancer cell-line models. PHYKPL expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PHYKPL is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PHYKPL protein abundance shows 27,472 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, KIRC, and LSCC as cancer lineages where PHYKPL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHYKPL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHYKPL survival associations across molecular data types. PHYKPL RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHYKPL RNA expression–survival associations across cancer types. High PHYKPL expression shows unfavorable associations in KICH, LGG and UVM, but favorable associations in SKCM, BLCA and THYM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PHYKPL RNA expression.
This table summarizes PHYKPL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PHYKPL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHYKPL shows lower tumor expression in THCA, LUSC, COAD, BRCA and UCEC and higher tumor expression in KIRC. The KIRC box plot shows higher PHYKPL RNA expression in tumor versus normal tissue (log2 FC = +1.513, t-test p < 0.001).
This table shows molecular features associated with PHYKPL in patient tissues and cancer cell lines. In patient samples, PHYKPL shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHYKPL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
